Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vets express concern over anthelmintic reclassification
Startect Dual Active Oral Solution for sheep has been reclassified from POM-V to POM-VPS.

Startect Dual Active Oral Solution changed from POM-V to POM-VPS

The Veterinary Medicines Directorate (VMD) has agreed to a request from Zoetis UK Limited to change the legal distribution category of Startect Dual Active Oral Solution for sheep.

The anthelmintic, which is authorised for the treatment and control of mixed gastro-intestinal nematode infections and associated diseases, has been changed from POM-V to POM-VPS. This means that pharmacists and suitably qualified persons, as well as vets, are now legally able to prescribe it.

In a press release, the BVA and the Sheep Veterinary Society voiced concern over the move. BVA junior vice president John Fishwick said:

"We know that resistance to anthelmintics is increasing in grazing animals worldwide and needs to be addressed to avoid a potentially disastrous situation of being unable to tackle parasites.

“The reclassification of Startect Dual Active from POM-V to POM-VPS is in direct opposition to the trend in Europe, where we are seeing increased control over dispensing of anthelmintics in species where resistance is posing a serious threat to animal health, welfare and profitable production; we're extremely concerned that we might start seeing resistance develop in Group 4 as a result.

“BVA believes that the prescribing of anthelmintics requires a level of control best provided by a veterinary surgeon who has the animals under his/her care, and is based on a sound clinical diagnosis. The drugs are best used as part of a flock health plan drawn up by farmers in conjunction with their vet in order to protect animal health and welfare and safeguard the efficacy of these products for the future."

Kathryn Dun, president of the Sheep Veterinary Society, added: “Group 4 anthelmintics should be used only as part of a careful designed strategy for the individual farm and it is imperative that this strategy is worked out with a vet and is part of a flock health plan for that farm. The products need to be used, in the correct way, to help prolong the life of our other anthelmintics.

“We are unlikely to have any further new groups of anthelmintics in the foreseeable future, so education of those buying and selling these products is crucial to ensure the longevity of the effective action of them against sheep parasites.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.